DekaBank Deutsche Girozentrale Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

DekaBank Deutsche Girozentrale lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 67.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,223 shares of the company’s stock after buying an additional 46,627 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Neurocrine Biosciences were worth $15,894,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Mather Group LLC. purchased a new position in Neurocrine Biosciences in the first quarter worth about $26,000. RFP Financial Group LLC boosted its position in Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Lindbrook Capital LLC boosted its position in Neurocrine Biosciences by 85.0% in the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares during the last quarter. EdgeRock Capital LLC purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $31,000. Finally, New Covenant Trust Company N.A. bought a new position in shares of Neurocrine Biosciences in the first quarter worth about $32,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Stephen A. Sherwin sold 40,000 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now owns 26,504 shares in the company, valued at $3,537,223.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Neurocrine Biosciences news, CFO Matt Abernethy sold 15,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares of the company’s stock, valued at $4,421,486.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen A. Sherwin sold 40,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,709 shares of company stock worth $11,009,150. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on NBIX. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, July 25th. Robert W. Baird lifted their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday. Royal Bank of Canada lifted their target price on Neurocrine Biosciences from $136.00 to $143.00 and gave the company a “sector perform” rating in a research note on Friday. Evercore ISI initiated coverage on Neurocrine Biosciences in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $175.00 price objective on the stock. Finally, Wells Fargo & Company raised Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $170.00 in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.16.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded down $0.01 on Friday, reaching $153.14. 799,316 shares of the stock traded hands, compared to its average volume of 781,810. The company has a fifty day moving average price of $139.82 and a 200-day moving average price of $138.41. The company has a market cap of $15.41 billion, a price-to-earnings ratio of 42.19 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 12 month low of $100.52 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.